Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Executive Summary

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

You may also be interested in...



Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks

Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.

What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today

The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.

Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures

Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel